# Myrcludex B vs Entecavir in Patients With HBeAg Negative Chronic Hepatitis B

> **NCT02881008** · PHASE1,PHASE2 · COMPLETED · sponsor: **Hepatera Ltd.** · enrollment: 48 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** Entecavir
- **DRUG:** Myrcludex B

## Key facts

- **NCT ID:** NCT02881008
- **Lead sponsor:** Hepatera Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11-14
- **Primary completion:** 2014-10-04
- **Final completion:** 2014-10-04
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2018-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02881008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02881008, "Myrcludex B vs Entecavir in Patients With HBeAg Negative Chronic Hepatitis B". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02881008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*